Table 1.
General information, laboratory tests, treatment, length of hospital stays.
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
|---|---|---|---|---|---|
| Sex | M | M | M | M | M |
| Age | 15 | 17 | 17 | 17 | 17 |
| BMI kg/m2 (WHO centiles) | 27 (95), obesity | 25.8 (95), obesity | 30 (97), obesity | 30 (99), obesity | 24.8 (89), overweight |
| Vaccine name | Pfizer-BioNTech | Pfizer-BioNTech | Pfizer-BioNTech | Pfizer-BioNTech | Pfizer-BioNTech |
| Dose number | 2 | 2 | 1 | 1 | 1 |
| Time (days) from vaccine to symptoms | 2 | 2 | 2 | 3 | 23 |
| Symptom description | Central, non-radiating chest pain, fever (37.8), | Central, non-radiating chest pain, fever (38.5), shoulder pain at the injection site, diarrhoea | Left-sided, non-radiating chest pain, fever (39), dry cough, | Left-sided, non-radiating chest pain | Central, radiating to the left shoulder chest pain, sore throat, fever (39) |
| Symptom duration (days) | 3 | 3 | 4 | 4 | 6 |
| Laboratory tests: | |||||
| COVID-19 PCR test at presentation | Negative | Negative | Negative | Negative | Negative |
| COVID-19 antibodies | |||||
| IgA and IgM class | Negative | Negative | Positive | Positive | Negative |
| IgG class | Positive | Positive | Positive | Positive | Positive |
| Troponin concentration | |||||
| Peak | 14,218.4 | 37,279.6 | 10,450.3 | 1895.2 | 1674 |
| Next troponin level (days after peak) | 102 (4) | 354.1 (3) | 327.0 (3) | 325 (3) | 360.0 (3) |
| Discharge (days after peak) | 12.4 (9) | 20.9 (13) | 18.5 (14) | 8.5 (12) | 1.5 (11) |
| Others: | |||||
| NT-proBNP | 269 | 27 | 50 | 259 | 391 |
| CRP | 3.0 | 3.9 | 3.9 | 0.7 | 40 |
| White blood cell count | 6.8 | 10.02 | 7.78 | 8.02 | 9.95 |
| Viral and bacterial serological tests | |||||
| Respiratory tract panel 1 | Negative | Negative | Negative | Negative | Negative |
| Neurological panel 2 | Negative | Negative | Negative | Negative | Negative |
| Rotavirus and adenovirus | Not obtained | Negative | Negative | Negative | Negative |
| Treatment | Lisinopril | Enalapril | Ramipril | Ramipril | Ramipril |
| Length of hospital stay (days) | 10 | 13 | 16 | 12 | 11 |
NT-proBNP, pq/mL, (N < 125); Troponin, ng/L (N < 19.0); CRP mg/dL, (N: 0.0–1.0); White blood cell count (N: 4–10 × 103/uL). 1 Respiratory tract panel—nasopharyngeal swab; PCR testing—adenovirus, mycoplasma pneumoniae, coronaviruses (HKU1, NL63, OC43, 229E), human metapneumovirus, human rhino/enterovirus, influenzas viruses (A, A/H1, A/H1-2009, A/H3, B, MERS), parainfluenza viruses (1, 2, 3, 4), RSV, SARS-CoV-2, Bordetella pertussis, Bordetella parapertusis, Chlamydophila pneumoniae. 2 Neurological panel, blood sample PCR testing—CMV, EBV, HSV1, HSV2, HSV6, HHV6, HHV7, Enterovirus, Adenovirus, Parechovirus, Parvovirus, ParvovirusB19.